Acquisition Announced
Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals
US$10bn equity value
Announced 6 Jul 2026 · NASDAQ: CRNX · US$85.00 cash per share
Advisers
Crinetics Pharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Vertex Pharmaceuticals Incorporated
Acquirer
- Financial adviser
- Legal adviser
Other advisers
- Financial adviser
- Target
- Crinetics Pharmaceuticals
- Acquirer
- Vertex Pharmaceuticals Incorporated
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma, Rare Disease
In the league tables
Similar deals
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Quince Therapeutics acquisition of Orphai Therapeutics May 2026 · Biotech
- Novartis acquisition of Avidity Biosciences Oct 2025 · US$11bn · Biotech
Sources
- Jul 2026 Kirkland Advises Vertex on $10 Billion Acquisition of Crinetics kirkland.com
- 6 Jul 2026 Crinetics Pharmaceuticals to be Acquired by Vertex Pharmaceuticals in $10 Billion Deal paulweiss.com
- 31 Jul 2026 Definitive merger proxy statement (DEFM14A), Crinetics Pharmaceuticals, Inc. sec.gov
- 1 Sep 2026 Lazard: UNITED STATES Vertex to Acquire Crinetics Pharmaceuticals lazard.com




